

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

PEO1

RRID:CVCL_2686

Type: Cell Line

Proper Citation

RRID:CVCL_2686

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2686

Proper Citation: RRID:CVCL_2686

Description: Cell line PEO1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: BRCA2 syndrome

Defining Citation: [PMID:1348364](#), [PMID:3167863](#), [PMID:3583449](#), [PMID:8824553](#), [PMID:9041185](#), [PMID:19654294](#), [PMID:20581869](#), [PMID:22183581](#), [PMID:22328975](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27235858](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:35028612](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PEO1

Synonyms: PE01, PEO-1, PEO

Cross References: BTO:BTO_0005796, EFO:EFO_0005445, ArrayExpress:E-MTAB-691, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:992, BioSample:SAMN03473296, cancercellines:CVCL_2686, CancerTools:151672, Cell_Model_Passport:SIDM00472, ChEMBL-Cells:ChEMBL4295441, ChEMBL-Targets:ChEMBL4296485, Cosmic:991317,

Cosmic:1102826, Cosmic:1305316, Cosmic:1524353, Cosmic:1709263, Cosmic-CLP:1480372, DepMap:ACH-001630, ECACC:10032308, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1480372, GEO:GSM185145, GEO:GSM185146, GEO:GSM459703, GEO:GSM459853, GEO:GSM711726, GEO:GSM723253, GEO:GSM743505, GEO:GSM851938, GEO:GSM1340589, GEO:GSM1670347, GEO:GSM4973221, GEO:GSM4973227, GEO:GSM4973233, GEO:GSM4973239, GEO:GSM4973245, GEO:GSM4973251, GEO:GSM4973257, GEO:GSM4973263, GEO:GSM4973269, PharmacDB:PE01_1260_2019, PRIDE:PXD003668, PRIDE:PXD020764, PRIDE:PXD030304, Progenetix:CVCL_2686, PubChem_Cell_line:CVCL_2686, Wikidata:Q54947162, Ximbio:151672

ID: CVCL_2686

Record Creation Time: 20220427T221430+0000

Record Last Update: 20260829T235628+0000

Ratings and Alerts

No rating or validation information has been found for PEO1.

No alerts have been found for PEO1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. *Molecular cancer therapeutics*.

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. *British journal of cancer*, 134(12), 1830.

Yamamoto TM, et al. (2026) Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. *Molecular cancer therapeutics*, 25(7), 1130.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Szmyd R, et al. (2025) Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage. *Nature cell biology*, 27(1), 59.

Woodruff ER, et al. (2025) Ablation of hematopoietic stem cell derived adipocytes reduces tumor burden in syngeneic mouse models of high-grade serous carcinoma. *bioRxiv : the preprint server for biology*.

Lake RJ, et al. (2025) Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer. *Cancer research communications*, 5(10), 1796.

Kenny HA, et al. (2025) Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. *Molecular cancer therapeutics*, 24(8), 1252.

Nie H, et al. (2024) Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade. *Nature communications*, 15(1), 2853.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. *iScience*, 27(7), 109978.

Leuzzi G, et al. (2024) SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. *Cell*, 187(4), 861.

Iwanaga R, et al. (2024) Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma. *Cancer research communications*, 4(8), 1919.

Persenaire C, et al. (2024) VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression. *Molecular carcinogenesis*, 63(7), 1248.

Pasquesi GIM, et al. (2024) Regulation of human interferon signaling by transposon exonization. *Cell*, 187(26), 7621.

Nguyen LL, et al. (2024) Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. *Molecular cancer therapeutics*, 23(9), 1332???1347.

McMellen A, et al. (2023) ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. *Molecular cancer research : MCR*, 21(1), 3.

Pasquesi GIM, et al. (2023) Regulation of human interferon signaling by transposon exonization. *bioRxiv : the preprint server for biology*.

Xu Y, et al. (2023) Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. *Cell reports*, 42(10), 113307.

Lombardi S, et al. (2023) Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer. *Cancer research communications*, 3(6), 1067.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.